HC Wainwright & Co. Reiterates Buy on Seaport Therapeutics, Maintains $50 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Seaport Therapeutics (NASDAQ:SPTX) with a Buy and maintains $50 price target.
Stocks · News reference
Seaport Therapeutics Reports Phase 1 Results; GlyphAllo At 375 mg Meets Primary Endpoint With No Driving Impairment; 250 mg Dose Also Achieves Key Secondary Endpoint
Trial met its primary endpoint, showing that evening dosing of GlyphAllo at 375 mg did not impair next-morning driving performance compared to placebo on Day 5, following multiple-day dosingKey secondary endpoint also
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Seaport Therapeutics shares are trading higher after Jones Trading initiated coverage on the stock with a Buy rating and announced a $32 price target.
Jones Trading Initiates Coverage On Seaport Therapeutics with Buy Rating, Announces Price Target of $32
Jones Trading analyst Justin Walsh initiates coverage on Seaport Therapeutics (NASDAQ:SPTX) with a Buy rating and announces Price Target of $32.